RESEARCH / PARTICIPATIONBack to the library
← Find a study
Recruiting · registry status

Testing a person’s own bone-marrow cells for neurological conditions

Researchers study delivery of cells taken from a person’s bone marrow through the bloodstream and nasal passages. The original record gives the procedures and risks.

Testing a treatment or activity · Study reference: NCT02795052

Plain-language introduction written with AI from the registry; not independently checked by a clinician. Read the original details below ↓

Open the official registry record ↗

Follow this study

Looking for volunteers

Start (reported actual date)
2016-06
Main measurements finished (planned)
2027-07-31
Study finished (planned)
2028-07-31

Planned dates can move. A study finishing does not tell us when a paper will be published.

No results summary has been confirmed in the registry records we imported. See connected papers below; we keep checking after recruitment ends.

Changes we have recorded
  • 2026-10-11 — recruiting

These are dates we observed a change, not necessarily the dates it happened.

Papers connected to this study

No connected paper has been found yet. The tracker checks the growing library for study identifiers and registry-linked publications.

Who can join?

Age 18 years and over · Does not accept healthy volunteers

These are starting points, not the full rules. The research team can tell you whether the study is right for your situation.

Read all the rules for taking part

Sex eligibility reported by registry: all

Inclusion Criteria: 1. Have documented functional damage to the central or peripheral nervous system unlikely to improve with present standard of care. 2. Be at least 6 months post-onset of the disease. 3. If under current medical therapy (pharmacologic or surgical treatment) for the condition be considered stable on that treatment and unlikely to have reversal of the associated neurologic functional damage as a result of the ongoing pharmacologic or surgical treatment. 4. In the estimation of Dr. Weiss and the neurologists have the potential for improvement with BMSC treatment and be at minimal risk of any potential harm from the procedure. 5. Be over the age of 18 and capable of providing informed consent. 6. Be medically stable and able to be medically cleared by their primary care physician or a licensed primary care practitioner for the procedure. Medical clearance means that in the estimation of the primary care practitioner, the patient can reasonably be expected to undergo the procedure without significant medical risk to health. Exclusion Criteria: 1. All patients must be capable of an adequate neurologic examination and evaluation to document the pathology. This will include the ability to cooperate with the exam. 2. Patients must be capable and willing to undergo follow up neurologic exams with the sub-investigators or their own neurologists as outlined in the protocol. 3. Patients must be capable of providing informed consent. 4. In the estimation of Dr. Weiss the BMSC collection and treatment will not present a significant risk of harm to the patient's general health or to their neurologic function. . 5. Patients who are not medically stable or who may be at significant risk to their health undergoing the procedure will not be eligible. 6. Women of childbearing age must not be pregnant at the time of treatment and should refrain from becoming pregnant for 3 months post treatment.
Full study name & original research details

Official study title

Neurologic Bone Marrow Derived Stem Cell Treatment Study

Short title used by the registry

Neurologic Stem Cell Treatment Study

Original description

This is a human clinical study involving the isolation of autologous bone marrow derived stem cells (BMSC) and transfer to the vascular system and inferior 1/3 of the nasal passages in order to determine if such a treatment will provide improvement in neurologic function for patients with certain neurologic conditions. http://mdstemcells.com/nest/

Further description from the registry

Various clinical studies have registered with the National Institutes of Health (NIH) to study neurologic diseases and damage. There have also been a number of journal reports of the benefits of treatment with BMSC for diseases and damage to nervous tissue. The investigators hope to add to the volume of literature regarding the use of BMSC in those neurologic diseases and conditions identified as likely to respond to this treatment. Intravenous administration of BMSC is a well-established approach to neurologic disease and injury with much support for its effectiveness in the pre-clinical and clinical literature. BMSC and the associated bone marrow fraction are posited to have a number of different mechanisms by which they may potentially improve neurologic function. In regards their ability to penetrate the blood-brain barrier for potential neuronal transdifferentiation and direct impact on the neurons and glial tissue within the brain, it should be remembered that within the diencephalon there are specific circumventricular organs which lie in the wall of the third ventricle. These are noteworthy for a significantly diminished blood-brain barrier and glial limitans which facilitates their function of coordinating homeostatic mechanisms of the endocrine and nervous systems. Therefore the investigators believe entry of BMSC may be facilitated in this area of the brain. The NEST Study provides a treatment Arm 1 which combines intravenous BMSC with topical application of BMSC to the lower 1/3 of the nasal passages as a means of introducing BMSC to the Central Nervous System (CNS). This is applied bilaterally to the inferior nasal conchas and meatuses. The Trigeminal Nerve or 5th Cranial Nerve is a paired, large sensory and motor nerve with multiple branches. It provides sensation to the surface and interior structures of the face including the nasal mucosa that lines the nose. The nerves of the Trigeminal Nerve providing sensation to this area converge and enter the brain at the level of the pons. There is documentation in the scientific literature that intranasal delivery of BMSC allows the BMSC to follow the pathways of the trigeminal nerve, facilitating entry into the parenchyma and cerebral spinal fluid (CSF) for effects on the CNS.

Conditions reported: Neurologic Disorders; Nervous System Diseases; Neurodegenerative Diseases; Neurological Disorders; Stroke; Traumatic Brain Injury; Cadasil; Chronic Traumatic Encephalopathy; Cerebral Infarction; Cerebral Ischemia; Cerebral Stroke; Cerebral Hemorrhage; Parkinson; Multi-System Degeneration; MSA - Multiple System Atrophy; Progressive Supranuclear Palsy; ALS; Amyotrophic Lateral Sclerosis; Neuropathy; Diabetic Neuropathies; Alzheimer Disease; Dementia; Frontotemporal Dementia; Lewy Body Disease; Cognitive Impairment; Lewy Body Variant of Alzheimer Disease

Registry records for this study

Records are joined using registration identifiers. Titles alone do not establish that two studies are the same.

Study type
Interventional
Interventions
Intravenous and Intranasal BMSC
Phases
NA
Sponsor
MD Stem Cells
Start date reported by registry
2016-06 (actual)

Registry updated: 2026-06-26 · Status last verified by the registry submitter: 2026-06

Registry records retrieved 2026-10-11 (UTC). Individual records may have older updates. Recruitment and eligibility must be confirmed with the study team.

Contact the research team

Public study contacts supplied to the registry. Ask whether recruitment is still open and what participation involves.

Steven Levy, MD · 203-423-9494 · stevenlevy@mdstemcells.com

Study locations

Site status can differ from overall study status. “Status not reported” means local availability needs confirmation. Remote participation and travel arrangements must be checked with the team.

MD Stem Cells

Westport, Connecticut, United States

Recruiting

Steven Levy, MD, Study Director · 203-423-9494 · stevenlevy@mdstemcells.com

203-423-9494

MD Stem Cells

Coral Springs, Florida, United States

Recruiting

Steven Levy, MD, Study Director · 203-423-9494 · stevenlevy@mdstemcells.com

203-423-9494

Steven Levy, MD

Jeffrey Weiss, MD

The Saudi-German Hospital

Dubai, United Arab Emirates, United Arab Emirates

Recruiting

Steven Levy, MD · (001) 203-423-9494 · stevenlevy@mdstemcells.com

Steven Levy · 001-203-423-9494 · stevenlevy@mdstemcells.com

Steven Levy, Study Director, MD

Jeffrey Weiss, MD

Facility not reported

United States

Status not reported

Facility not reported

United Arab Emirates

Status not reported

Facility not reported

Austria

Status not reported

The original descriptions and participation rules come from the registry. Participation is voluntary and does not guarantee benefit.